COVAXIN phase 3 data shows 78% efficacy against Covid

New Delhi, 12/9: The homegrown Covid-19 vaccine Covaxin on Thursday received long-awaited scientific credence with one of the world’s top medical journals publishing the final trial results showing its ability to offer 78 per cent protection against symptomatic Covid-19 and 93 per cent against severe disease.   The indigenous vaccine’s phase 3 clinical trial carried…

Read More